Short Interest in Kamada Ltd. (NASDAQ:KMDA) Decreases By 78.9%

Kamada Ltd. (NASDAQ:KMDA - Get Free Report) saw a large drop in short interest during the month of February. As of February 28th, there was short interest totalling 35,100 shares, a drop of 78.9% from the February 13th total of 166,100 shares. Approximately 0.1% of the shares of the company are short sold. Based on an average daily trading volume, of 194,200 shares, the short-interest ratio is presently 0.2 days.

Wall Street Analyst Weigh In

KMDA has been the topic of several recent analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $11.00 target price on shares of Kamada in a research note on Thursday, March 6th. StockNews.com upgraded Kamada from a "buy" rating to a "strong-buy" rating in a research report on Thursday.

Kamada Stock Performance

Shares of KMDA stock traded down $0.05 during mid-day trading on Friday, hitting $7.18. 72,437 shares of the stock traded hands, compared to its average volume of 251,340. Kamada has a twelve month low of $4.74 and a twelve month high of $9.15. The firm has a market cap of $412.71 million, a price-to-earnings ratio of 25.64, a price-to-earnings-growth ratio of 0.97 and a beta of 0.97. The company's 50-day simple moving average is $7.23 and its 200-day simple moving average is $6.22.

Remove Ads

Kamada Dividend Announcement

The business also recently announced a -- dividend, which will be paid on Monday, April 7th. Investors of record on Monday, March 17th will be issued a $0.20 dividend. The ex-dividend date is Monday, March 17th.

Hedge Funds Weigh In On Kamada

Hedge funds have recently modified their holdings of the stock. Plato Investment Management Ltd acquired a new position in shares of Kamada in the 3rd quarter worth $117,000. Public Employees Retirement System of Ohio purchased a new position in shares of Kamada during the third quarter valued at $77,000. JPMorgan Chase & Co. purchased a new position in shares of Kamada during the fourth quarter valued at $67,000. Geode Capital Management LLC grew its holdings in shares of Kamada by 5.6% during the fourth quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company's stock valued at $178,000 after buying an additional 1,549 shares in the last quarter. Finally, NewEdge Advisors LLC grew its holdings in shares of Kamada by 54.2% during the fourth quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company's stock valued at $143,000 after buying an additional 8,260 shares in the last quarter. 20.38% of the stock is currently owned by institutional investors and hedge funds.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.